U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Untreated Childhood Rhabdomyosarcoma

MedGen UID:
856814
•Concept ID:
C3897220
•
Finding

Definition

A finding of childhood rhabdomyosarcoma that has not been treated. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUntreated Childhood Rhabdomyosarcoma

Professional guidelines

PubMed

A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors.
Castello MA, Clerico A, Jenkner A, Dominici C
Pediatr Hematol Oncol 1990;7(2):129-35. doi: 10.3109/08880019009033382. PMID: 2206854
Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma.
Etcubanas E, Horowitz M, Vogel R
Cancer Treat Rep 1985 Sep;69(9):999-1000. PMID: 4028041
Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA, Cook RL, Lutz PJ, Houghton PJ
Cancer Treat Rep 1985 Jan;69(1):91-6. PMID: 3967262

Recent clinical studies

Etiology

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS, Bonig H, Ivics Z, Ullrich E, Klingebiel T, Bader P, Rettinger E
Front Immunol 2020;11:581468. Epub 2020 Oct 19 doi: 10.3389/fimmu.2020.581468. PMID: 33193388Free PMC Article
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS
Cancer Med 2019 Oct;8(14):6437-6448. Epub 2019 Aug 27 doi: 10.1002/cam4.2504. PMID: 31456361Free PMC Article
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC
J Clin Oncol 2012 Jul 10;30(20):2457-65. Epub 2012 Jun 4 doi: 10.1200/JCO.2011.40.3287. PMID: 22665534
Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.
Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M
BMC Cancer 2009 Aug 28;9:304. doi: 10.1186/1471-2407-9-304. PMID: 19715595Free PMC Article
Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
Koscielniak E, Jürgens H, Winkler K, Bürger D, Herbst M, Keim M, Bernhard G, Treuner J
Cancer 1992 Nov 15;70(10):2557-67. doi: 10.1002/1097-0142(19921115)70:10<2557::aid-cncr2820701027>3.0.co;2-8. PMID: 1482503

Diagnosis

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS
Cancer Med 2019 Oct;8(14):6437-6448. Epub 2019 Aug 27 doi: 10.1002/cam4.2504. PMID: 31456361Free PMC Article
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC
J Clin Oncol 2012 Jul 10;30(20):2457-65. Epub 2012 Jun 4 doi: 10.1200/JCO.2011.40.3287. PMID: 22665534
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G, Pondarré C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A
Biochimie 1998 Mar;80(3):271-80. doi: 10.1016/s0300-9084(98)80009-6. PMID: 9615866
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA
Cancer Chemother Pharmacol 1992;31(3):229-39. doi: 10.1007/BF00685553. PMID: 1464161
Terminal deoxynucleotidyltransferase distribution in neoplastic and hematopoietic cells.
Greenwood MF, Coleman MS, Hutton JJ, Lampkin B, Krill C, Bolium FJ, Holland P
J Clin Invest 1977 May;59(5):889-99. doi: 10.1172/JCI108711. PMID: 265945Free PMC Article

Therapy

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS, Bonig H, Ivics Z, Ullrich E, Klingebiel T, Bader P, Rettinger E
Front Immunol 2020;11:581468. Epub 2020 Oct 19 doi: 10.3389/fimmu.2020.581468. PMID: 33193388Free PMC Article
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC
J Clin Oncol 2012 Jul 10;30(20):2457-65. Epub 2012 Jun 4 doi: 10.1200/JCO.2011.40.3287. PMID: 22665534
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O
J Clin Oncol 2005 Apr 20;23(12):2618-28. Epub 2005 Feb 22 doi: 10.1200/JCO.2005.08.130. PMID: 15728225
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G, Pondarré C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A
Biochimie 1998 Mar;80(3):271-80. doi: 10.1016/s0300-9084(98)80009-6. PMID: 9615866
Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.
Houghton JA, Cook RL, Lutz PJ, Houghton PJ
Eur J Cancer Clin Oncol 1984 Jul;20(7):955-60. doi: 10.1016/0277-5379(84)90170-6. PMID: 6430707

Prognosis

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS, Bonig H, Ivics Z, Ullrich E, Klingebiel T, Bader P, Rettinger E
Front Immunol 2020;11:581468. Epub 2020 Oct 19 doi: 10.3389/fimmu.2020.581468. PMID: 33193388Free PMC Article
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS
Cancer Med 2019 Oct;8(14):6437-6448. Epub 2019 Aug 27 doi: 10.1002/cam4.2504. PMID: 31456361Free PMC Article
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O
J Clin Oncol 2005 Apr 20;23(12):2618-28. Epub 2005 Feb 22 doi: 10.1200/JCO.2005.08.130. PMID: 15728225
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G, Pondarré C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A
Biochimie 1998 Mar;80(3):271-80. doi: 10.1016/s0300-9084(98)80009-6. PMID: 9615866
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA
Cancer Chemother Pharmacol 1992;31(3):229-39. doi: 10.1007/BF00685553. PMID: 1464161

Clinical prediction guides

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS, Bonig H, Ivics Z, Ullrich E, Klingebiel T, Bader P, Rettinger E
Front Immunol 2020;11:581468. Epub 2020 Oct 19 doi: 10.3389/fimmu.2020.581468. PMID: 33193388Free PMC Article
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS
Cancer Med 2019 Oct;8(14):6437-6448. Epub 2019 Aug 27 doi: 10.1002/cam4.2504. PMID: 31456361Free PMC Article
Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.
Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M
BMC Cancer 2009 Aug 28;9:304. doi: 10.1186/1471-2407-9-304. PMID: 19715595Free PMC Article
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O
J Clin Oncol 2005 Apr 20;23(12):2618-28. Epub 2005 Feb 22 doi: 10.1200/JCO.2005.08.130. PMID: 15728225
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G, Pondarré C, Boland I, Cappelli C, Santos A, Thomas C, Lucchi E, Imadalou K, Pein F, Morizet J, Gouyette A
Biochimie 1998 Mar;80(3):271-80. doi: 10.1016/s0300-9084(98)80009-6. PMID: 9615866

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...